Vertex (VRTX) EVP David Altshuler earns 11,194 performance-based shares

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive David Altshuler reported stock awards tied to performance goals. On 01/22/2026, he acquired 7,866 shares of Vertex common stock and another 3,328 shares, each at a price of $0 per share, reflecting earned performance shares from prior performance stock unit awards. These awards were originally granted on 02/01/2023 and 02/12/2025 and included performance-vesting requirements that the company’s management development and compensation committee certified as achieved on 01/22/2026. After these transactions, Altshuler directly owned 34,477 shares of Vertex common stock. The 7,866-share portion is scheduled to vest on 02/13/2026, and the 3,328-share portion will vest in installments beginning on 02/24/2026.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider ALTSHULER DAVID

Role EVP, Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,866	$0.00	--
Grant/Award	Common Stock	3,328	$0.00	--

Holdings After Transaction: Common Stock — 31,149 shares (Direct)

Footnotes (1)

1. Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026. Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ALTSHULER DAVID

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		A		7,866(1)	A	$0	31,149	D
Common Stock	01/22/2026		A		3,328(2)	A	$0	34,477	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.

2. Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider in this Vertex (VRTX) Form 4 filing?

The insider is David Altshuler, who serves as EVP, Chief Scientific Officer of Vertex Pharmaceuticals Incorporated.

What transactions did David Altshuler report in this Vertex (VRTX) Form 4?

On 01/22/2026, Altshuler reported two acquisitions of Vertex common stock: 7,866 shares and 3,328 shares, both at a price of $0 per share, as part of earned performance stock awards.

How many Vertex (VRTX) shares does David Altshuler own after these transactions?

Following the reported transactions, David Altshuler directly owned 34,477 shares of Vertex Pharmaceuticals common stock.

What is the source of the 7,866 Vertex (VRTX) shares reported by David Altshuler?

The 7,866 shares represent earned performance shares from a performance stock unit award granted on 02/01/2023 that had performance-vesting requirements, which were certified as achieved on 01/22/2026.

What is the source of the 3,328 Vertex (VRTX) shares reported by David Altshuler?

The 3,328 shares represent earned performance shares from a performance stock unit award granted on 02/12/2025, with performance-vesting requirements certified on 01/22/2026.

When will the earned performance shares for David Altshuler vest at Vertex (VRTX)?

The 7,866 shares are scheduled to vest on 02/13/2026, and the 3,328 shares will vest in installments beginning on 02/24/2026.

Are David Altshuler’s reported Vertex (VRTX) shares held directly or indirectly?

The Form 4 indicates that Altshuler’s 34,477 shares of Vertex common stock are held with direct (D) ownership.